{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:18:06Z","timestamp":1792873086370,"version":"4.5.0"},"reference-count":35,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"German Research Foundation DFG","award":["DE 614\/16-1"],"award-info":[{"award-number":["DE 614\/16-1"]}]},{"name":"Physician-Scientist Program of Heidelberg University, Faculty of Medicine","award":["DE 614\/16-1"],"award-info":[{"award-number":["DE 614\/16-1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>(1) Background: Magnetic-resonance (MR)-guided stereotactic body radiotherapy (SBRT) allows for ablative, non-invasive treatment of liver metastases. However, long-term clinical outcome data are missing. (2) Methods: Patients received MR-guided SBRT with a MRIdian Linac between January 2019 and October 2021 and were part of an ongoing prospective observational registry. Local hepatic control (LHC), distant hepatic control (DHC), progression free survival (PFS) and overall survival (OS) were estimated with the Kaplan\u2013Meier method. Toxicity was documented according to CTCAE (v.5.0). (3) Results: Forty patients were treated for a total of 54 liver metastases (56% with online plan adaptation). Median prescribed dose was 50 Gy in five fractions equal to a biologically effective dose (BED) (alpha\/beta = 10 Gy) of 100 Gy. At 1 and 2 years, LHC was 98% and 75%, DHC was 34% and 15%, PFS was 21% and 5% and OS was 83% and 57%. Two-year LHC was higher in case of BED &gt; 100 Gy (100% vs. 57%; log-rank p = 0.04). Acute grade 1 and 2 toxicity (mostly nausea) occurred in 26% and 7% of the patients, with no grade \u2265 3 event. (4) Conclusions: To our knowledge, this is the largest cohort of MR-guided liver SBRT. Long-term local control was promising and underscores the aim of achieving &gt;100 Gy BED. Nonetheless, distant tumor control remains challenging.<\/jats:p>","DOI":"10.3390\/cancers15102786","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T01:58:06Z","timestamp":1684288686000},"page":"2786","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Long-Term Clinical Results of MR-Guided Stereotactic Body Radiotherapy of Liver Metastases"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1731-7090","authenticated-orcid":false,"given":"Fabian","family":"Weykamp","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"},{"name":"National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany"},{"name":"Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Hoegen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"},{"name":"National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany"},{"name":"Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Regnery","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"},{"name":"National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany"},{"name":"Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5795-1999","authenticated-orcid":false,"given":"Efthimios","family":"Katsigiannopulos","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Katharina","family":"Renkamp","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"},{"name":"National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"K\u00f6nig","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"},{"name":"National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Sandrini","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"},{"name":"National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7087-9581","authenticated-orcid":false,"given":"Eva","family":"Meixner","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"},{"name":"National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Rippke","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Buchele","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Liermann","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"},{"name":"National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Debus","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"},{"name":"National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany"},{"name":"Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"},{"name":"Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Side, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kl\u00fcter","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"H\u00f6rner-Rieber","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"},{"name":"National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany"},{"name":"Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.prro.2015.10.011","article-title":"Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases","volume":"6","author":"Goodman","year":"2016","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Andratschke, N., Alheid, H., Allg\u00e4uer, M., Becker, G., Blanck, O., Brunner, T., Duma, M., Gerum, S., Guckenberger, M., and Hildebrandt, G. (2018). The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): Patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4191-2"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ijrobp.2017.07.030","article-title":"Local Control Outcomes Using Stereotactic Body Radiation Therapy for Liver Metastases From Colorectal Cancer","volume":"99","author":"Joo","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ijrobp.2004.05.025","article-title":"A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and\/or inferior vena cava tumor thrombus","volume":"61","author":"Zeng","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fonc.2012.00023","article-title":"Stereotactic body radiation therapy for patients with heavily pretreated liver metastases and liver tumors","volume":"2","author":"Lanciano","year":"2012","journal-title":"Front. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/jrr\/rrw008","article-title":"Threshold doses and prediction of visually apparent liver dysfunction after stereotactic body radiation therapy in cirrhotic and normal livers using magnetic resonance imaging","volume":"57","author":"Doi","year":"2016","journal-title":"J. Radiat. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.ijrobp.2009.05.071","article-title":"Radiation dose-volume effects in the stomach and small bowel","volume":"76","author":"Kavanagh","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijrobp.2017.12.290","article-title":"Radiation Dose-Volume Effects for Liver SBRT","volume":"110","author":"Miften","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/j.ijrobp.2012.06.005","article-title":"Predictor of Severe Gastroduodenal Toxicity After Stereotactic Body Radiotherapy for Abdominopelvic Malignancies","volume":"84","author":"Bae","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3109\/0284186X.2015.1062541","article-title":"Comparison of onboard low-field magnetic resonance imaging versus onboard computed tomography for anatomy visualization in radiotherapy","volume":"54","author":"Noel","year":"2015","journal-title":"Acta Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.radonc.2014.11.005","article-title":"Impact of inadequate respiratory motion management in SBRT for oligometastatic colorectal cancer","volume":"113","author":"Engels","year":"2014","journal-title":"Radiother. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ijrobp.2016.01.033","article-title":"Time-Resolved Intrafraction Target Translations and Rotations During Stereotactic Liver Radiation Therapy: Implications for Marker-based Localization Accuracy","volume":"95","author":"Bertholet","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.radonc.2014.05.007","article-title":"Kilovoltage intrafraction motion monitoring and target dose reconstruction for stereotactic volumetric modulated arc therapy of tumors in the liver","volume":"111","author":"Poulsen","year":"2014","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.3109\/0284186X.2013.813638","article-title":"Variations in magnitude and directionality of respiratory target motion throughout full treatment courses of stereotactic body radiotherapy for tumors in the liver","volume":"52","author":"Worm","year":"2013","journal-title":"Acta Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s00066-014-0714-1","article-title":"Stereotactic body radiotherapy for liver tumors","volume":"190","author":"Sterzing","year":"2014","journal-title":"Strahlenther. Und Onkol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.semradonc.2009.11.004","article-title":"Adaptive management of liver cancer radiotherapy","volume":"20","author":"Brock","year":"2010","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.ijrobp.2018.05.048","article-title":"MR-guided Gated Stereotactic Radiation Therapy Delivery for Lung, Adrenal, and Pancreatic Tumors: A Geometric Analysis","volume":"102","author":"Palacios","year":"2018","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejmp.2020.07.027","article-title":"Assessment of online adaptive MR-guided stereotactic body radiotherapy of liver cancers","volume":"77","author":"Padgett","year":"2020","journal-title":"Phys. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13014-021-01813-6","article-title":"Benefit of replanning in MR-guided online adaptive radiation therapy in the treatment of liver metastasis","volume":"16","author":"Mayinger","year":"2021","journal-title":"Radiat. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Rogowski, P., von Bestenbostel, R., Walter, F., Straub, K., Nierer, L., Kurz, C., Landry, G., Reiner, M., Auernhammer, C.J., and Belka, C. (2021). Feasibility and Early Clinical Experience of Online Adaptive MR-Guided Radiotherapy of Liver Tumors. Cancers, 13.","DOI":"10.3390\/cancers13071523"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13014-022-02021-6","article-title":"Dosimetric benefit of MR-guided online adaptive radiotherapy in different tumor entities: Liver, lung, abdominal lymph nodes, pancreas and prostate","volume":"17","author":"Nierer","year":"2022","journal-title":"Radiat. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Bordeau, K., Michalet, M., Keskes, A., Valdenaire, S., Debuire, P., Cantaloube, M., Cabaill\u00e9, M., Jacot, W., Draghici, R., and Demontoy, S. (2023). Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12031183"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ctro.2020.11.014","article-title":"Marker-less online MR-guided stereotactic body radiotherapy of liver metastases at a 1.5 T MR-Linac\u2014Feasibility, workflow data and patient acceptance","volume":"26","author":"Gani","year":"2021","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.adro.2018.08.005","article-title":"A Multi-Institutional Experience of MR-Guided Liver Stereotactic Body Radiation Therapy","volume":"4","author":"Rosenberg","year":"2019","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00066-020-01603-1","article-title":"Definition and quality requirements for stereotactic radiotherapy: Consensus statement from the DEGRO\/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery","volume":"196","author":"Guckenberger","year":"2020","journal-title":"Strahlenther. Und Onkol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"610637","DOI":"10.3389\/fonc.2021.610637","article-title":"Magnetic resonance-guided stereotactic body radiotherapy of liver tumors: Initial clinical experience and patient-reported outcomes","volume":"11","author":"Weykamp","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Weykamp, F., Katsigiannopulos, E., Piskorski, L., Regnery, S., Hoegen, P., Ristau, J., Renkamp, C.K., Liermann, J., Forster, T., and Lang, K. (2022). Dosimetric Benefit of Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy of Liver Metastases. Cancers, 14.","DOI":"10.3390\/cancers14246041"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00066-020-01578-z","article-title":"First prospective clinical evaluation of feasibility and patient acceptance of magnetic resonance-guided radiotherapy in Germany","volume":"196","author":"Katayama","year":"2020","journal-title":"Strahlenther. Und Onkol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ctro.2019.04.007","article-title":"Technical design and concept of a 0.35 T MR-Linac","volume":"18","year":"2019","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.radonc.2017.07.028","article-title":"Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer","volume":"125","author":"Bohoudi","year":"2017","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3389\/fonc.2019.00263","article-title":"Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy","volume":"9","author":"Jin","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"658753","DOI":"10.3389\/fimmu.2021.658753","article-title":"Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijrobp.2017.12.288","article-title":"Local Control After Stereotactic Body Radiation Therapy for Liver Tumors","volume":"110","author":"Ohri","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13014-022-02033-2","article-title":"MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): A randomized controlled phase II trial","volume":"17","author":"Hoegen","year":"2022","journal-title":"Radiat. Oncol."},{"key":"ref_35","unstructured":"Leclerc, C.G.F. (2023, February 20). Adaptative MR-Guided Stereotactic Body Radiotherapy of Liver Tumors (RASTAF). ClinicalTrials.gov2020, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04242342."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/10\/2786\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:36:30Z","timestamp":1760124990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/10\/2786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["cancers15102786"],"URL":"https:\/\/doi.org\/10.3390\/cancers15102786","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,17]]}}}